Our Services
Others
- DFPP
- Shockwave
- IV Drip
If a diabetic wound has not healed after 4 weeks of good care, it is not too late, but it is time to change the plan. Wounds that shrink by less than about half in the first 4 weeks rarely close by 12 weeks with the same treatment. At that point, specialists first recheck the basics: blood flow, infection, pressure on the wound and blood sugar. Then they consider advanced therapies.
This guide explains the “4 weeks and 50 percent” check in plain words. It compares the main advanced options, including negative pressure therapy, oxygen therapies, skin substitutes and umbilical cord mesenchymal stem cells (UC-MSCs), with an honest evidence level for each. It also covers wounds on the leg and surgical wounds, not just the foot.
A diabetic wound is called “non-healing” or “chronic” when it stops improving despite proper care. Most stalled diabetic wounds have the same underlying causes, so treatment always starts with them:
The International Working Group on the Diabetic Foot (IWGDF) stresses that advanced therapies should only be used where this best standard of care has not healed the wound on its own (IWGDF 2023). No advanced treatment, including stem cells, can make up for a wound that is still under pressure, infected or short of blood.
Four weeks is the key checkpoint. By then, a wound that is going to heal with standard care should already be clearly smaller. If it is not, the chance it will close on the current plan is low.
It is a simple progress check. Measure the wound at the start of good care, then again 4 weeks later:
This rule comes from a 2003 study of 203 patients. It found that diabetic foot wounds that did not shrink by at least half in the first 4 weeks had less than a 10% chance of closing by week 12 (Houston et al., Transitioning to advanced therapies for DFUs: are four weeks and 50 percent magic numbers?). Later trial data showed the same pattern. Only about 4% of ulcers with less than 50% reduction at 4 weeks healed by week 12, compared with more than half of those that reached 50% (Lower Extremity Review).
The rule is a guide, not a guarantee. One wound specialist describes it as useful for showing which way a wound is heading, but right only about 70% of the time (HMP Global, SAWC Fall). Its real value is that it forces a decision at 4 weeks instead of waiting months.
You or your nurse can work it out in three steps:
Example: a wound measures 4 cm × 3 cm = 12 cm² at the start. After 4 weeks it measures 3 cm × 2.5 cm = 7.5 cm². The reduction is (12 − 7.5) ÷ 12 × 100 = 37.5%. That is below 50%, so the treatment plan should be reviewed.
Weekly photos with a ruler in the frame make tracking much easier, and they are useful for a specialist review.
Do not wait for the 4-week check if you notice any of these. Contact your doctor the same day:
Go to emergency care if you have a fever with a red, hot, swollen foot, or if the skin turns dark or black. These can be signs of serious infection or loss of blood supply.
Not every stalled diabetic wound is a foot ulcer. The same principles apply elsewhere, but the cause, and so the basic treatment, can differ.
Leg wounds in people with diabetes are often caused, or made worse, by poor vein function (venous ulcers), narrowed arteries (arterial ulcers), or a mix of both. The right treatment depends on which it is:
The 4-week, 50% check is also used for venous leg ulcers to decide when to step up treatment (HMP Global).
After an amputation, debridement surgery or other operation, a wound in a person with diabetes may open up again or heal slowly. For surgical foot wounds, the IWGDF suggests considering negative pressure wound therapy as an add-on to standard care (IWGDF 2023 outreach slides). Infection and blood flow still need to be checked first.
Once the basics are in place and the wound is still stalled, these are the main advanced options. The table shows what the IWGDF 2023 guideline says about each (IWGDF 2023; IWGDF outreach slides; Chen et al., full guideline).
| Therapy | How it works | IWGDF 2023 position | Evidence level |
| Negative pressure wound therapy (NPWT) | A sealed dressing and pump apply gentle suction to the wound | Consider for surgical foot wounds; do not use for non-surgical foot ulcers | Low |
| Hyperbaric oxygen therapy (HBOT) | Breathing pure oxygen in a pressurised chamber | Consider for ischaemic or neuro-ischaemic ulcers when standard care has failed | Low |
| Topical oxygen therapy | Oxygen delivered directly onto the wound | Consider when standard care has failed | Low |
| Skin substitutes (placental-derived products) | A tissue sheet placed on the wound acts as a scaffold and releases growth signals | Consider when standard care has failed | Low |
| Cell therapies, including UC-MSCs | Cells release signals that calm inflammation and support new blood vessels | Not suggested outside research (“other cell therapy”) | Low |
Evidence levels follow the IWGDF’s own grading. “Low” means the evidence comes from a limited number of trials, often small, with some risk of bias.
Hyperbaric oxygen raises oxygen levels throughout the body and in the wound. The IWGDF suggests considering it for ulcers with reduced blood flow when standard care has failed. It requires daily sessions, often 30 to 40 or more, in a specialised centre. UC-MSCs work differently. They mainly calm inflammation and send signals that encourage new small blood vessels, and they are given in a few applications. HBOT is in the guideline; stem cell therapy is not yet. Neither has been directly compared with the other in a large trial.
| 📌 If you’re interested in how MSCs shift the immune system from attack mode to repair mode, we have an interesting article that discusses mesenchymal stem cell therapy for immune modulation, which you can read via the internal link. |
NPWT is well established for surgical wounds, such as after a partial foot amputation. For ordinary diabetic foot ulcers that were not caused by surgery, the IWGDF recommends against using it, because it has not been shown to beat standard care. Stem cells are being studied for stalled ulcers where the wound bed itself seems “stuck”. In some cases the two may be used together, for example NPWT after surgery followed by other treatment if healing stalls.
Skin substitutes, especially placental-derived membranes, are placed on the wound and act as a scaffold that also releases growth signals. The IWGDF suggests considering placental-derived products when standard care has failed. UC-MSCs are living cells rather than a tissue sheet, and the IWGDF does not yet suggest them outside research. Both aim to restart healing in a stalled wound bed. Skin substitutes currently have more trial evidence and guideline support.
Topical oxygen therapy delivers oxygen straight onto the wound through a small device, often at home. In 2019 the IWGDF advised against it. In 2023, after newer trials, it changed this to a conditional recommendation to consider it when standard care has failed (IWGDF 2019; IWGDF 2023 outreach slides). It is less demanding than hyperbaric oxygen, but it does not replace the need for good blood flow.
Umbilical cord mesenchymal stem cells (UC-MSCs) come from the Wharton’s jelly of umbilical cords donated after healthy births. A laboratory screens them and grows them to a treatment dose. They are applied around or onto the wound, usually by small injections into the healthy wound edge, or in a gel spread on the wound bed.
| 📌 If you’re interested in why umbilical cord cells are often preferred over bone marrow or fat-derived cells, we have an interesting article that discusses why UC-MSCs are superior to other stem cell sources, which you can read via the internal link. |
They do not turn into new skin. Instead, they release growth factors and tiny vesicles called exosomes that:
These effects target the “stuck inflammation” that keeps many chronic diabetic wounds from moving forward.
What the evidence shows, honestly: small clinical trials of stem cell treatments for diabetic foot ulcers have reported faster healing than standard care alone. However, the IWGDF 2023 guideline reviewed cell therapies and concluded: “We suggest not using other cell therapy as an adjunct therapy to standard of care” (Conditional; Low) (Chen et al., IWGDF 2023). In plain words, the evidence is not yet strong enough for routine use. UC-MSC therapy should be seen as a research-based option for carefully selected patients, given under an approved protocol, not as a proven treatment.
In Thailand, stem cell use outside a short list of blood disorders must take place within research approved by the Medical Council of Thailand (The Nation, 2024).
| 📌 If you’re planning treatment in Thailand and want a practical checklist for choosing a safe clinic, we have an interesting article that discusses whether stem cell therapy is safe in Thailand, which you can read via the internal link. |
“Regenerative medicine” covers treatments that help the body rebuild tissue rather than just protect a wound. For diabetic wounds, this includes placental-derived skin substitutes, the autologous leucocyte, platelet and fibrin patch (made from the patient’s own blood), and cell therapies such as UC-MSCs. Among these, the IWGDF currently gives conditional support to placental-derived products and the leucocyte/platelet/fibrin patch, but not to other cell therapies.
UC-MSC therapy may be worth discussing with a specialist when all of the following are true:
It is usually considered after, or alongside, guideline-supported options such as offloading improvements, oxygen therapy or skin substitutes, not instead of them.
Dead tissue, slough and thick callus act as a barrier. They hold bacteria, block new tissue from growing and stop treatments from reaching living cells. Sharp debridement removes this layer down to healthy, bleeding tissue. That gives the stem cells, or any advanced therapy, a living wound bed to work on. The IWGDF recommends sharp debridement as standard care for diabetic foot ulcers.
Yes. An active infection drives inflammation, destroys new tissue and can spread. Bone infection in particular must be diagnosed, for example with an X-ray, MRI or bone biopsy, and treated with antibiotics, surgery or both. Adding cells to an infected wound wastes the treatment and can delay proper care.
HbA1c shows your average blood sugar over the past 2 to 3 months. High glucose weakens immune cells, slows new tissue growth and makes infection more likely. That is why every wound review should include a recent HbA1c result.
There is no single “magic number” for wound healing. Your diabetes doctor will set a target that is safe for you, balancing better control against the risk of low blood sugar. Practical steps include:
Healing a wound uses extra protein and energy. Many people with long-standing diabetic wounds, especially older adults, are not eating enough. Good everyday nutrition supports healing:
Ask for a dietitian review if you have lost weight without trying, have a poor appetite, or have kidney disease, which changes protein needs. Special supplements are worth taking only if a test or a dietitian shows you need them.
If your wound has not shrunk by half after 4 weeks of care, a fresh look can help you decide what to do next. Send us via WhatsApp or our consultation form:
Our medical team will review your case and tell you honestly what we think the next step should be, whether that is better offloading, a vascular review, a guideline-supported advanced therapy, or a UC-MSC protocol. We will tell you clearly if stem cell therapy is not the right choice for you.